MediWound to Report Third Quarter 2023 Financial Results

Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) to release Q3 2023 financial results on November 21, 2023. The company will host a conference call and webcast to discuss the results and provide corporate updates.

Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time

YAVNE, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the third quarter ended September 30, 2023 on Tuesday, November 21, 2023.

Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.

Dial-in and call details are as follows:

Conference Call & Webcast Details

Toll-Free:		1-833-630-1956
Israel:		1-80-921-2373
International:		1-412-317-1837
Webcast:		Click HERE

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid^®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx^®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study.

For more information visit www.mediwound.com and follow the Company on LinkedIn.

MediWound Contacts:

Hani Luxenburg		Daniel Ferry
Chief Financial Officer		Managing Director
MediWound Ltd.		LifeSci Advisors, LLC
ir@mediwound.com		daniel@lifesciadvisors.com

FAQ

When will MediWound Ltd. release its Q3 2023 financial results?

MediWound Ltd. will release its Q3 2023 financial results on Tuesday, November 21, 2023.

What is the dial-in number for the conference call?

The dial-in number for the conference call is Toll-Free: 1-833-630-1956, Israel: 1-80-921-2373, International: 1-412-317-1837.

Where can I access the archived version of the webcast?

The archived version of the webcast will be available for replay on the Investors section of the MediWound website.